diff --git a/DESCRIPTION b/DESCRIPTION index 301a76f72..b8a29a3a8 100644 --- a/DESCRIPTION +++ b/DESCRIPTION @@ -1,5 +1,5 @@ Package: AMR -Version: 3.0.1.9107 +Version: 3.0.1.9108 Date: 2026-10-10 Title: Antimicrobial Resistance Data Analysis Description: Functions to simplify and standardise antimicrobial resistance (AMR) diff --git a/NEWS.md b/NEWS.md index 76da189b1..75ff41e55 100644 --- a/NEWS.md +++ b/NEWS.md @@ -1,4 +1,4 @@ -# AMR 3.0.1.9107 +# AMR 3.0.1.9108 Planned as v3.1.0, mid October 2026. diff --git a/index.Rmd b/index.Rmd index 751f21883..132c5f7b1 100644 --- a/index.Rmd +++ b/index.Rmd @@ -15,6 +15,8 @@ knitr::opts_chunk$set( ) options(width = 100) AMR:::reset_all_thrown_messages() +# wisca() uses Monte Carlo simulations, so fix the seed to keep the output (and index.md) stable between builds +set.seed(1) ``` # The `AMR` Package for R diff --git a/index.md b/index.md index c3843cd22..9bfe20d87 100644 --- a/index.md +++ b/index.md @@ -225,7 +225,7 @@ wisca(example_isolates, | Piperacillin/tazobactam | Piperacillin/tazobactam + Gentamicin | Piperacillin/tazobactam + Tobramycin | |:------------------------|:-------------------------------------|:-------------------------------------| -| 70% (64.7-75.3%) | 93.6% (92.1-95%) | 89.8% (86.7-92.4%) | +| 69.8% (64.5-74.7%) | 93.6% (92.1-95%) | 89.9% (87-92.5%) | WISCA supports stratification by any clinical variable, so you can generate syndrome-specific or ward-specific coverage estimates: @@ -240,9 +240,9 @@ wisca(example_isolates, | Syndromic Group | Piperacillin/tazobactam | Piperacillin/tazobactam + Gentamicin | Piperacillin/tazobactam + Tobramycin | |:----------------|:------------------------|:-------------------------------------|:-------------------------------------| -| Clinical | 74.7% (68.7-80.4%) | 93.6% (91.9-95.2%) | 90.4% (86.9-93.1%) | -| ICU | 56.9% (48.5-65.6%) | 86.7% (83.2-89.7%) | 83% (78.2-87.2%) | -| Outpatient | 57.4% (46-68.9%) | 76.6% (70.7-82.3%) | 67.5% (57.2-77.3%) | +| Clinical | 74.6% (69.1-80.1%) | 93.7% (92.1-95.1%) | 90.3% (87-93.1%) | +| ICU | 56.9% (48.3-66%) | 86.7% (83.5-89.8%) | 83% (77.9-87.4%) | +| Outpatient | 57.7% (46.5-69.3%) | 76.6% (70.5-82.2%) | 67.8% (56.9-77.5%) | **For AMR surveillance**, traditional antibiograms remain the right tool for tracking resistance per species over time: